A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Citarinostat (Primary) ; Nivolumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 01 Nov 2017 Planned End Date changed from 31 Dec 2017 to 11 Oct 2018.
- 01 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 11 Oct 2018.
- 18 Oct 2017 Results (n=13, data cut off: 16 June 2017) presented at the 18th World Conference on Lung Cancer